Trophos says TRO40303 significantly reduces myocardial infarct size and improves cardiac function

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced demonstration of proof of principle that its proprietary compound, TRO40303 significantly reduces myocardial infarct size and improves cardiac function. The company presented information on two posters at the European Society of Cardiology (ESC) Congress 2009 held in Barcelona, Spain from 29 August to 2nd September. 

Trophos expects the new presentations to help identify and obtain partners for this highly promising program for further development and commercialisation.